Ozempic: FDA Orders GLP-1 Labeling Changes Due to Eye Disease Risk
The Food and Drug Administration (FDA) announced on November 9 that it will require drugmakers to add information to the warning labels of Ozempic, Wegovy, Mounjaro, Zepbound and other GLP-1 medications about “a potential increased risk” of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). GLP-1 medications are approved to treat type […]
